This transporter is important in the hepatic elimination of rosuvastatin.Systemic exposure of rosuvastatin increases in proportion to dose. Genkend medicin As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. ... Tabletter. Specific tests for effects on hERG have not been evaluated. The risk of myopathy (including rhabdomyolysis) is increased when rosuvastatin is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. The clinical relevance of this interaction has not been studied.Concomitant use of rosuvastatin and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in CWhen it is necessary to co-administer rosuvastatin with other medicinal products known to increase exposure to rosuvastatin, doses of rosuvastatin should be adjusted. LDL apheresis) or if such treatments are not appropriate.Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see section 5.1), as an adjunct to correction of other risk factors.Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.Effects on skeletal muscle e.g. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of rosuvastatin 40 mg. In situations where co-administration of these medicinal products with rosuvastatin is unavoidable, the benefit and the risk of concurrent treatment and rosuvastatin dosing adjustments should be carefully considered (see section 4.5).Rosuvastatin may be given at any time of day, with or without food.- in patients with hypersensitivity to the active substance or to any of the excipients listed in section 6.1.- in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3× the upper limit of normal (ULN).- in patients with severe renal impairment (creatinine clearance < 30 ml/min).- during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.The 40 mg dose is contraindicated in patients with pre-disposing factors for myopathy/rhabdomyolysis. The 40 mg dose is contraindicated in some of these patients (see section 4.3).Rosuvastatin is a substrate of various transporter proteins (e.g. The elimination half-life does not increase at higher doses. Instruktionsfilm Min.medicin.dk har det fulde ansvar for præparatbeskrivelserne. Excipients with known effect: lactose monohydrate and sodium. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.If treatment with systemic fusidic acid is necessary, rosuvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Zentiva, One Onslow Street, Guildford, Surrey, GU1 4YS, UKTo bookmark a medicine you must sign up and log in.To view the changes to a medicine you must sign up and log in. Det skyldes, at min.medicin.dk kan have suppleret Lægemiddelstyrelsens og producentens produktinformationer med andre kilder. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (> or equal to 1 g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone.